GRTS — Gritstone bio Share Price
0.000.00%
Last trade - 00:00- $78.02m
- $38.89m
- $16.34m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.5 | ||
| Price to Tang. Book | 1.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.77 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -92.81% | ||
| Return on Equity | -124.41% | ||
| Operating Margin | -854.26% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.37 | 4.04 | 48.21 | 19.95 | 16.34 | 13.96 | 47.34 | 68.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.
Directors
- Elaine Jones CHM (66)
- Andrew Allen PRE (55)
- Vassiliki Economides CFO (41)
- Erin Jones COO (49)
- Rahsaan Thompson EVP (50)
- Matthew Hawryluk EVP (43)
- Raphael Rousseau EVP (52)
- Vijay Yabannavar EVP (60)
- James Cho CAO
- Karin Jooss VRD (56)
- Shefali Agarwal DRC (47)
- Naiyer Rizvi DRC
- Clare Fisher IND
- Richard Heyman IND (63)
- Steve Krognes IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 5th, 2015
- Public Since
- September 28th, 2018
- No. of Shareholders
- 16
- No. of Employees
- 231
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 105,918,748
- Address
- 5959 HORTON STREET, SUITE 300, EMERYVILLE, 94608
- Web
- https://gritstonebio.com/
- Phone
- +1 5108716100
- Auditors
- Ernst & Young LLP
Upcoming Events for GRTS
Gritstone bio Inc Annual Shareholders Meeting
Q2 2024 Gritstone bio Inc Earnings Release
Similar to GRTS
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
What is the Gritstone bio share price?
As of Today at 19:09 UTC, shares in Gritstone bio are trading at $0.74. This share price information is delayed by 15 minutes.
How has the Gritstone bio share price performed this year?
Shares in Gritstone bio last closed at $0.74 and the price had moved by -71.34% over the past 365 days. In terms of relative price strength the Gritstone bio share price has underperformed the S&P500 Index by -76.15% over the past year.
What are the analyst and broker recommendations for Gritstone bio?
The overall consensus recommendation for Gritstone bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Gritstone bio dividend yield?
Gritstone bio does not currently pay a dividend.
Does Gritstone bio pay a dividend?
Gritstone bio does not currently pay a dividend.
When does Gritstone bio next pay dividends?
Gritstone bio does not currently pay a dividend.
How do I buy Gritstone bio shares?
To buy shares in Gritstone bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gritstone bio?
As of the previous close price of $0.74, shares in Gritstone bio had a market capitalisation of $78.02m.
Where are Gritstone bio shares listed?
Here are the trading details for Gritstone bio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: GRTS
What kind of share is Gritstone bio?
Based on an overall assessment of its quality, value and momentum Gritstone bio is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gritstone bio share price forecast for 2024?
The analyst consensus target price for shares in Gritstone bio is $5.17. That is 601.87% above the last closing price of $0.74.
Analysts covering Gritstone bio currently have a consensus Earnings Per Share (EPS) forecast of -$1.05 for the next financial year.
What is the trend in the Gritstone bio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gritstone bio. Over the past six months, its share price has underperformed the S&P500 Index by -69.04%.
As of the last closing price of $0.74, shares in Gritstone bio were trading -61.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gritstone bio PE Ratio?
The Gritstone bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.74.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gritstone bio?
Gritstone bio's management team is headed by:
- Elaine Jones - CHM
- Andrew Allen - PRE
- Vassiliki Economides - CFO
- Erin Jones - COO
- Rahsaan Thompson - EVP
- Matthew Hawryluk - EVP
- Raphael Rousseau - EVP
- Vijay Yabannavar - EVP
- James Cho - CAO
- Karin Jooss - VRD
- Shefali Agarwal - DRC
- Naiyer Rizvi - DRC
- Clare Fisher - IND
- Richard Heyman - IND
- Steve Krognes - IND